DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Information source: Mahidol University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Strongyloidiasis

Intervention: Ivermectin (Drug); ivermectin (Drug); Albendazole (Drug)

Phase: Phase 3

Status: Enrolling by invitation

Sponsored by: Mahidol University

Official(s) and/or principal investigator(s):
Yupin Suputtamongkol, MD, Principal Investigator, Affiliation: Mahidol University


A prospective controlled trial to compare the efficacy and safety of 7-day albendazole, single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.

Clinical Details

Official title: Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: cure rate

Secondary outcome: safety


Minimum age: 18 Years. Maximum age: 90 Years. Gender(s): Both.


Inclusion Criteria:

- Patients with positive strongyloides larva in the stool

Exclusion Criteria:

- Pregnancy

- Lactating women

- Known allergy to any study drug

Locations and Contacts

Siriraj Hospital, Bangkoknoi, Bangkok 10700, Thailand
Additional Information

Starting date: July 2008
Last updated: June 18, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017